-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Andi Kang (Wuxi) Co.
, Ltd.
independent research and development of biotechnology for the treatment and prevention of influenza, clinical trials of new drug candidates apply ADC189 of influenza B (IND), won the Chinese State Drug Administration Bureau Center for Drug Evaluation ( CDE) implied license
.
, Ltd.
independent research and development of biotechnology for the treatment and prevention of influenza, clinical trials of new drug candidates apply ADC189 of influenza B (IND), won the Chinese State Drug Administration Bureau Center for Drug Evaluation (CDE) Implied permission
.
Andi Kang (Wuxi) Co.
Infect
ADC189 has a new anti-influenza mechanism, which can directly inhibit virus replication
.
It belongs to the Cap-dependent endonuclease inhibitor, which inhibits the CAP cap structure-dependent endonuclease in influenza virus
Antikang Bio's design and development of ADC189 aims to combat influenza A and B viruses, including influenza strains resistant to oseltamivir and avian influenza strains (H7N9, H5N1)
.
The data of the "head-to-head" study shows that compared to another drug with the same target, ADC189 has the safety advantages of no central nervous system side effects, oral absorption is not affected by food, and a higher safe dose, showing "best- "in-class" characteristics
Avian Influenza
It is worth mentioning that a single oral dose of this new drug under development can block influenza virus replication within 24 hours
.
This is expected to bring great convenience to patients' medication
According to Dr.
Weiping Jiang, founder of Antikang Bio, the approval of ADC189 for clinical use is a milestone for the company
.
At present, the Antikang biological team has launched a phase 1 clinical study, led by top clinical experts in the field of anti-infection, to evaluate ADC189 for the treatment and prevention of influenza A and B in newborns, adolescents, adults, and the elderly.
"We will accelerate the clinical process of ADC189, and strive to become the first class 1 innovative anti-influenza drug independently developed and approved for marketing in China, bringing new solutions that can be "healed" and "reached" for patients in China and the world
.
" Dr.
The Antikang bioscientist team has long focused on the research and development of small molecule innovative drugs in the field of anti-infection
.
Since the establishment of the company, a pragmatic and efficient R&D team has established a R&D pipeline containing 8 drug candidates in only 2 years
It is understood that Antikang Bio is currently conducting a round A financing of up to 60 million yuan, and Clearing Capital is acting as the exclusive financial advisor for this financing
Leave a message here